Drug profile · INN
evinacumab-dgnb
EVKEEZA
evinacumab-dgnb (EVKEEZA) is a angiopoietin-related protein 3 inhibitor. Associated with Regeneron UK Limited. Route of administration: injection. Current US regulatory status: approved.
Drug details — evinacumab-dgnb
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 6
- Data quality
- 0.89
Quick answer
evinacumab-dgnb (EVKEEZA) is a angiopoietin-related protein 3 inhibitor. Associated with Regeneron UK Limited. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Angiopoietin-related protein 3 inhibitor
Primary target: Angiopoietin-related protein 3
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is evinacumab-dgnb?
evinacumab-dgnb (EVKEEZA) is a angiopoietin-related protein 3 inhibitor. Associated with Regeneron UK Limited. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for evinacumab-dgnb?
EVKEEZA is a marketed brand name for evinacumab-dgnb. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of evinacumab-dgnb?
evinacumab-dgnb has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.